Company / Current Liabilities per Share
CytomX Therapeutics, Inc. Current Liabilities per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities per Share
$0.34
FY2025
5-year range
$0.34 / $2.32
FY2021-FY2025
Trend
-68.4%
vs FY2024
Sector context
#172 of 210
Health Care
What the data says
CytomX Therapeutics, Inc.'s current liabilities per share of $0.34 is lower than 82% of companies in the Health Care sector (FY2025). Current Liabilities per Share has fluctuated over the past 10 years, ranging from $0.34 in FY2025 to $2.32 in FY2023.
Based on SEC 10-K filings.
0.34 in FY2025 with a 5-year CAGR of -31.4%.
Improved from $2.32 to $0.34 over the past 2 years.
Health Care sector context is included.
Current Liabilities per Share over time
Growth rates
- 3-Year CAGR
- -47.3%
- 5-Year CAGR
- -31.4%
- 10-Year CAGR
- -
Sector benchmark
-98.6% below sector average
Key checks
Key Insights
- In FY2025, current liabilities per share decreased 68.4% year-over-year.
- Ranks #172 out of 210 companies in the Health Care sector.
- Peak current liabilities per share was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.68 (distress zone, below 1.8 threshold)
- Strong profit margin: 23.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current Liabilities per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.34 | -68.4% |
| FY2024 | $1.07 | -53.8% |
| FY2023 | $2.32 | +0.5% |
| FY2022 | $2.30 | +41.7% |
| FY2021 | $1.63 | -26.7% |
| FY2020 | $2.22 | +17.9% |
| FY2019 | $1.88 | -13.4% |
| FY2018 | $2.17 | +36.7% |
| FY2017 | $1.59 | +62.1% |
| FY2016 | $0.98 | -93.8% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026